Galderma smiling on frown lines and crow's feet data
Privately-held Swiss dermatology company Galderma has turned a frown into a smile in sharing the latest news on its drug relabotulinumtoxinA (QM-1114), a novel liquid formulation botulinum toxin A.
Last month, the US Food and Drug Administration issued a Complete Response Letter regarding Galderma’s Biologics License Application for relabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines, or frown lines, associated with corrugator or procerus muscle activity as well as moderate-to-severe lateral canthal lines, known as crow’s feet, associated with orbicularis oculi muscle activity.
On Thursday, the company changed the narrative by announcing positive topline results from two Phase IIIb trials investigating relabotulinumtoxinA for the treatment of these conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze